Shilpa Medicare (NSE:SHILPAMED) Growth Rank: 10 (As of Sep. 22, 2026) — 43% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHILPAMED Shilpa Medicare Ltd NSE:SHILPAMED
72 GF Score
Price ₹1,070.80
GF Value ₹455.00
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shilpa Medicare Growth Rank?

Shilpa Medicare NSE:SHILPAMED +6.55% 72 Growth Rank is 10 as of Sep. 22, 2026, which is 43% above its 10-year median of 7.00. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 72/100 and a GF Value™ of ₹455.00 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shilpa Medicare has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Shilpa Medicare Growth Rank Related Terms

NSE:SHILPAMED vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shilpa Medicare Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Growth Rank distribution charts can be found below:

* The bar in red indicates where Shilpa Medicare's Growth Rank falls into.


NSE:SHILPAMED
72GF Score
Shilpa Medicare Ltd NSE:SHILPAMED
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Shilpa Medicare (NSE:SHILPAMED) has a Growth Rank of 10 as of Sep. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Shilpa Medicare and its competitors. This is 43% above median its historical median of 7.00. Over the past decade, Shilpa Medicare's Growth Rank has ranged from 1.00 to 10.00.
Is Shilpa Medicare's Growth Rank too high?
Shilpa Medicare's current Growth Rank of 10 is 43% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Shilpa Medicare has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Growth Rank compare to ZTS?
Shilpa Medicare's Growth Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Shilpa Medicare's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Shilpa Medicare and its competitors. Shilpa Medicare's current Growth Rank is 10, which is 43% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹455.00, compared to a current price of ₹1,070.80 — trading 135.3% above its estimated fair value. The current Growth Rank is 10, which is 43% above median its 10-year median of 7.00. Shilpa Medicare's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Growth Rank is 10 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹1,070.80 is trading 135.3% above its estimated GF Value™ of ₹455.00. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for NSE:SHILPAMED:

  • Growth Rank: 10 (43% above median its 10-year median of 7.00)
  • GF Value™: ₹455.00 vs. price of ₹1,070.80 (135.3% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shilpa Medicare Business Description

Other Exchanges 530549:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
72GF Score

Get the complete analysis for NSE:SHILPAMED

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,070.80
Price
₹455.00
GF Value